Cargando…
Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
The efficacy of Covid-19 vaccine in hematopoietic stem cell transplantation (HSCT) recipients is still unknown. We planned a prospective study to evaluate the immune response after the administration of Covid-19 vaccine in HSCT recipients. Fifty patients previously submitted to HSCT (38 autologous a...
Autores principales: | Chiarucci, Martina, Paolasini, Sara, Isidori, Alessandro, Guiducci, Barbara, Loscocco, Federica, Capalbo, Maria, Visani, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451475/ https://www.ncbi.nlm.nih.gov/pubmed/34552880 http://dx.doi.org/10.3389/fonc.2021.737300 |
Ejemplares similares
-
Treatment options for acute myeloid leukemia patients aged <60 years
por: Visani, Giuseppe, et al.
Publicado: (2022) -
SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone
por: Visani, Giuseppe, et al.
Publicado: (2020) -
Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021) -
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021) -
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)